Primary Hepatocellular Carcinoma
11
0
0
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
9.1%
1 terminated out of 11 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (11)
A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma
H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
Clinical Study of MAK Immune Cells in the Treatment of PHC
Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma
Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media